FILTER
LATEST INTERVIEWS
Richard Pino
VICE PRESIDENT SALES AND MARKETING, LATIN AMERICA, CRODA DO BRASIL
Recent acquisitions and investments have considerably enlarged Croda's presence in Brazil both in manufacturing and in R&D with its new innovation center at Campinas.
Richard Peters
PRESIDENT AND CEO, MERRIMACK PHARMACEUTICALS
Merrimack Pharmaceuticals is focused on cancer treatment through a deeper understanding of cancer pathways and biological markers.
Ankit Mahadevia & Cristina Larkin
CEO & CHIEF COMMERCIAL OFFICER, SPERO THERAPEUTICS
Spero Therapeutics is developing new antimicrobial drugs to substitute those that have become ineffectual as they meeting resistance.
Stefan Lepecki
CEO, BRASKEM IDESA
"We work very closely with Pemex and are very confident in their ability."
A. Hawkshaw & E. Antúnez de Mayolo
BEAR CREEK MINING CORPORATION
"There is only one chance to build a project correctly"
Cristhian Perez & Ralf van der Ven
VOPAK
“Typically, we see elections as times of uncertainty. However, in the coming year we do not expect a huge impact on the business environment since our business relies on short or long-term positions for basic products.”
Will Ansley
PRESIDENT AND CEO, LUPAKA GOLD
"Invicta is a high-grade resource, so it can withstand varying metal prices."
Ignacio Bustamante
CEO, HOCHSCHILD MINING
"Crypto-currencies are taking funds away from gold and silver."
Travis McCready
PRESIDENT & CEO, MASSACHUSETTS LIFE SCIENCES CENTER
The Massachusetts Life Sciences Center has spent a billion dollars to ensure the best possible environment for the life sciences industry.
J. Rogelio Garza Garza
UNDERSECRETARY OF INDUSTRY AND COMMERCE, MINISTRY OF ECONOMY
The Undersecretary of Industry and Commerce explains its policies towards driving growth for Mexico’s steel industry.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
